ENDS EVALI VALI THCVALI: Difference between revisions

Line 3:

<br>

<big>'''“E-cigarette or Vaping Product Use-Associated Lung Injury” (EVALI) -- Right Illness, Wrong Name. Will The CDC Correct It?'''</big>

~~<big>~~'''~~“E-cigarette or Vaping Product Use-Associated Lung Injury” (EVALI)~~'''~~</big>~~

='''Communication With The CDC'''=

*In chronological order. These are quotes from the linked sources.

=~~Right Illness, Wrong Name. Will The CDC Correct It?~~=

==Letters==

==

==Articles, Op-Eds, Blogs, Media==

='''Misperceptions, Misinformation, Disinformation'''=

*Newest to oldest. These are quotes from the linked sources.

==Journals==

===2026: [https://www.sciencedirect.com/science/article/pii/S0306460326000821 Shifting perceptions of e-cigarette risk: A secondary analysis from a nationwide, randomized controlled clinical trial of e-cigarettes among smokers]===

*Media coverage surrounding e-cigarette or vaping product use-associated lung injury (EVALI) may have played a role in the changing relative harm perceptions about e-cigarettes and other tobacco products. The goal of the present study was to compare relative risk perceptions for cigarettes and e-cigarettes before, during, and after EVALI.

*Relative risk perceptions for e-cigarettes differed between enrollment cohorts in this study. Results suggest that the onset of EVALI may have impacted relative risk perceptions for e-cigarettes, such that there was an increase in relative risk perceptions; i.e., e-cigarettes were perceived as increasingly harmful in comparison to combustible cigarettes.

**Citation: Barros EM, Ferreira AC, Neelon B, Ravenel IE, Carpenter MJ, Smith TT. Shifting perceptions of e-cigarette risk: A secondary analysis from a nationwide, randomized controlled clinical trial of e-cigarettes among smokers. Addict Behav. 2026 Jul;178:108672. doi: 10.1016/j.addbeh.2026.108672. Epub 2026 Mar 15. PMID: 41865464.

***Acknowledgment: Funding for the parent study was provided by the National Cancer Institute (R01CA210625 to MJC). Ms. Barros was supported by a grant from the National Institute on Drug Abuse (R25DA020537). Ms. Ravenel was supported by the SC CHEER YES program funded by Hollings Cancer Center and TD Bank. MJC has served as a paid expert in e-cigarette litigation within the past 3 years.

===2022: [https://onlinelibrary.wiley.com/doi/10.1111/add.16097 United States public health officials need to correct e-cigarette health misinformation]===

*Despite the evidence, the CDC continues including ‘e-cigarettes’ in the name EVALI. This naming has affected news coverage and contributed to distorted consumer beliefs about the risks of nicotine vaping. Smokers are twice as likely to incorrectly identify nicotine e-cigarettes as the cause of EVALI than to correctly identify illicit, adulterated THC products.

*This increased perceived risk is associated with a 30% reduction in both e-cigarette demand and reduced use of e-cigarettes for smoking cessation.

**Pesko MF, Cummings KM, Douglas CE, Foulds J, Miller T, Rigotti NA, Warner KE. United States public health officials need to correct e-cigarette health misinformation. Addiction. 2023 May;118(5):785-788. doi: 10.1111/add.16097. Epub 2022 Dec 12. PMID: 36507802.

***Acknowledgment: M.F.P. reports recent funding from the National Institutes of Health, Food and Drug Administration Center for Tobacco Products; American Cancer Society; Virginia Foundation for Healthy Youth; the University of Kentucky’s Institute for the Study of Free Enterprise; and Health Canada. N.A.R.'s research is primarily funded by the National Institutes of Health. She has also received research funding from and consulted with Achieve Life Sciences to evaluate an investigational smoking cessation medication. K.M.C. has served as a paid expert witness in litigation filed against cigarette manufacturers. J.F. has recently performed paid consulting for Johnson & Johnson pharmaceutical company on smoking cessation medicines and has received a research grant from the National Jewish Health (healthcare organization) on telephone smoking cessation counseling. His research on e-cigarettes is funded by the National Institutes of Health (NIDA). C.D. is a co-principal investigator for research conducted through the Center for the Assessment of Tobacco Regulations, which is funded by NIH/FDA. He is also an advisor to the Smoking Cessation Leadership Center at the University of California San Francisco relating to behavioral health and tobacco use. K.E.W.’s research is supported in part by a Tobacco Center of Regulatory Science grant to the University of Michigan and Georgetown University from the Food and Drug Administration and National Cancer Institute (award no. U54CA229974). T.M. is the acting Attorney General for the State of Iowa and is responsible for representing the state in any legal matters. The opinions expressed in this article are the authors’ own and do not necessarily reflect the views of any of the organizations and government agencies that have provided support to the authors.

==Articles, Op-Eds, Blogs, Media==

===2026: [https://www.news-medical.net/news/20260504/EVALI-outbreak-reshaped-public-perceptions-of-e-cigarette-harm.aspx EVALI outbreak reshaped public perceptions of e-cigarette harm]===

*During the EVALI outbreak and in the years that followed, participants viewed e-cigarettes as significantly riskier compared with cigarettes than they had before the outbreak. That shift persisted even after scientists identified the cause: vitamin E acetate, an additive found primarily in illicit THC vaping products, not standard nicotine e-cigarettes.

**Citation: News-Medical. (2026, May 4). EVALI outbreak reshaped public perceptions of e-cigarette harm. Retrieved June 6, 2026.

===2022: [https://filtermag.org/vape-misinformation-surgeon-general/ End Vape Misinformation, Tobacco Control Experts Urge Surgeon General]===

*The authors, who include Ken Warner of the University of Michigan, Nancy Rigotti of Harvard Medical School and Thomas Miller, the departing attorney general of Iowa, also call on the CDC to correct the name “EVALI,” or “e-cigarette, or vaping, product-use associated lung injury”—the outbreak that peaked in the fall of 2019. Originally and loudly misattributed to nicotine vaping products, the condition has since been linked to vitamin E acetate, a cutting agent found in illicit THC cartridges. Even now, US public health agencies have not explicitly corrected the record.

*Citation: Norcia, A. (2022, December 15). End vape misinformation, tobacco control experts urge Surgeon General. Filter. Retrieved June 6, 2026.

==Community Notes on X==

=Lung Injury Research (EVALI)=

*Newest to oldest. These are quotes from the linked sources.

==Journals==

==Articles, Op-Eds, Blogs, Media==

---------------------------------

===2021: [https://drive.google.com/file/d/1XMJ_JiqyiEa-bpcG4Ev7XyCROSt9k8RM/view Request by 75 experts to CDC to rename EVALI]===

@@ Line 3: / Line 3: @@
 <br>
 <br>
+<big>'''“E-cigarette or Vaping  Product Use-Associated Lung Injury” (EVALI) -- Right Illness, Wrong Name. Will The CDC Correct It?'''</big>
-<big>'''“E-cigarette or Vaping  Product Use-Associated Lung Injury” (EVALI)'''</big>
+='''Communication With The CDC'''=
+*In chronological order. These are quotes from the linked sources.
-=Right Illness, Wrong Name. Will The CDC Correct It?=
+==Letters==
-==
+==Articles, Op-Eds, Blogs, Media==
+='''Misperceptions, Misinformation, Disinformation'''=
+*Newest to oldest. These are quotes from the linked sources.
+==Journals==
+===2026: [https://www.sciencedirect.com/science/article/pii/S0306460326000821 Shifting perceptions of e-cigarette risk: A secondary analysis from a nationwide, randomized controlled clinical trial of e-cigarettes among smokers]===
+*Media coverage surrounding e-cigarette or vaping product use-associated lung injury (EVALI) may have played a role in the changing relative harm perceptions about e-cigarettes and other tobacco products. The goal of the present study was to compare relative risk perceptions for cigarettes and e-cigarettes before, during, and after EVALI.
+*Relative risk perceptions for e-cigarettes differed between enrollment cohorts in this study. Results suggest that the onset of EVALI may have impacted relative risk perceptions for e-cigarettes, such that there was an increase in relative risk perceptions; i.e., e-cigarettes were perceived as increasingly harmful in comparison to combustible cigarettes.
+**Citation: Barros EM, Ferreira AC, Neelon B, Ravenel IE, Carpenter MJ, Smith TT. Shifting perceptions of e-cigarette risk: A secondary analysis from a nationwide, randomized controlled clinical trial of e-cigarettes among smokers. Addict Behav. 2026 Jul;178:108672. doi: 10.1016/j.addbeh.2026.108672. Epub 2026 Mar 15. PMID: 41865464.
+***Acknowledgment: Funding for the parent study was provided by the National Cancer Institute (R01CA210625 to MJC). Ms. Barros was supported by a grant from the National Institute on Drug Abuse (R25DA020537). Ms. Ravenel was supported by the SC CHEER YES program funded by Hollings Cancer Center and TD Bank. MJC has served as a paid expert in e-cigarette litigation within the past 3 years.
 ===2022: [https://onlinelibrary.wiley.com/doi/10.1111/add.16097 United States public health officials need to correct e-cigarette health misinformation]===
+*Despite the evidence, the CDC continues including ‘e-cigarettes’ in the name EVALI. This naming has affected news coverage and contributed to distorted consumer beliefs about the risks of nicotine vaping. Smokers are twice as likely to incorrectly identify nicotine e-cigarettes as the cause of EVALI than to correctly identify illicit, adulterated THC products.
+*This increased perceived risk is associated with a 30% reduction in both e-cigarette demand and reduced use of e-cigarettes for smoking cessation.
+**Pesko MF, Cummings KM, Douglas CE, Foulds J, Miller T, Rigotti NA, Warner KE. United States public health officials need to correct e-cigarette health misinformation. Addiction. 2023 May;118(5):785-788. doi: 10.1111/add.16097. Epub 2022 Dec 12. PMID: 36507802.
+***Acknowledgment: M.F.P. reports recent funding from the National Institutes of Health, Food and Drug Administration Center for Tobacco Products; American Cancer Society; Virginia Foundation for Healthy Youth; the University of Kentucky’s Institute for the Study of Free Enterprise; and Health Canada. N.A.R.'s research is primarily funded by the National Institutes of Health. She has also received research funding from and consulted with Achieve Life Sciences to evaluate an investigational smoking cessation medication. K.M.C. has served as a paid expert witness in litigation filed against cigarette manufacturers. J.F. has recently performed paid consulting for Johnson & Johnson pharmaceutical company on smoking cessation medicines and has received a research grant from the National Jewish Health (healthcare organization) on telephone smoking cessation counseling. His research on e-cigarettes is funded by the National Institutes of Health (NIDA). C.D. is a co-principal investigator for research conducted through the Center for the Assessment of Tobacco Regulations, which is funded by NIH/FDA. He is also an advisor to the Smoking Cessation Leadership Center at the University of California San Francisco relating to behavioral health and tobacco use. K.E.W.’s research is supported in part by a Tobacco Center of Regulatory Science grant to the University of Michigan and Georgetown University from the Food and Drug Administration and National Cancer Institute (award no. U54CA229974). T.M. is the acting Attorney General for the State of Iowa and is responsible for representing the state in any legal matters. The opinions expressed in this article are the authors’ own and do not necessarily reflect the views of any of the organizations and government agencies that have provided support to the authors.
+==Articles, Op-Eds, Blogs, Media==
+===2026: [https://www.news-medical.net/news/20260504/EVALI-outbreak-reshaped-public-perceptions-of-e-cigarette-harm.aspx EVALI outbreak reshaped public perceptions of e-cigarette harm]===
+*During the EVALI outbreak and in the years that followed, participants viewed e-cigarettes as significantly riskier compared with cigarettes than they had before the outbreak. That shift persisted even after scientists identified the cause: vitamin E acetate, an additive found primarily in illicit THC vaping products, not standard nicotine e-cigarettes.
+**Citation: News-Medical. (2026, May 4). EVALI outbreak reshaped public perceptions of e-cigarette harm. Retrieved June 6, 2026.
 ===2022: [https://filtermag.org/vape-misinformation-surgeon-general/ End Vape Misinformation, Tobacco Control Experts Urge Surgeon General]===
+*The authors, who include Ken Warner of the University of Michigan, Nancy Rigotti of Harvard Medical School and Thomas Miller, the departing attorney general of Iowa, also call on the CDC to correct the name “EVALI,” or “e-cigarette, or vaping, product-use associated lung injury”—the outbreak that peaked in the fall of 2019. Originally and loudly misattributed to nicotine vaping products, the condition has since been linked to vitamin E acetate, a cutting agent found in illicit THC cartridges. Even now, US public health agencies have not explicitly corrected the record.
+*Citation: Norcia, A. (2022, December 15). End vape misinformation, tobacco control experts urge Surgeon General. Filter. Retrieved June 6, 2026.
+==Community Notes on X==
+=Lung Injury Research (EVALI)=
+*Newest to oldest. These are quotes from the linked sources.
+==Journals==
+==Articles, Op-Eds, Blogs, Media==
+---------------------------------
 ===2021: [https://drive.google.com/file/d/1XMJ_JiqyiEa-bpcG4Ev7XyCROSt9k8RM/view Request by 75 experts to CDC to rename EVALI]===